De-risk therapeutic development through early identification of candidate biomarkers and clinical evaluation of companion diagnostics (CDx, Japanese market only). Use our biomarker discovery services and CDx development to advance your preclinical and clinical therapeutic candidates with:
Robust and sensitive biomarkers are paramount to identifying the right patient population and cancer indication(s) for specific therapeutics, including combination therapies. Our biomarker discovery expertise spans a wide range of disciplines to guide every step of the process, and overcome your internal data, resource, and analysis challenges.
Achieve the optimal outcome for clinical trials with biomarkers that are statistically accurate and biologically relevant.
Identify, qualify, and validate biomarkers through our integrated biomarker testing services using: